Its Challenge Network seeks to attract new investigators and new ideas to focus on cross-disease cell biology.
Health records from 31 million French people suggest that drinking to excess is a major risk factor for early onset dementia.
Ionis Pharmaceuticals reported positive top-line data from the Phase 1/2a trial of its ASO.
Screen identifies antibody that induces mouse bone marrow cells to differentiate and travel to the brain, where they clear plaques.
Overexpressing miR-132 dampened AD pathology in young mice, and appeared to nourish the birth of new hippocampal neurons in older animals.
For their work on modifiable dementia risk factors and dementia in the oldest old, respectively, Kristine Yaffe and Claudia Kawas split this year’s coveted award in neurodegeneration research.
A broadening drug development pipeline now contains Phase 1 or 2 drugs on targets unrelated to Aβ or tau.
A winter storm cut the meeting short, but not before attendees learned that viral load correlates with clinical and pathological traits of AD.
World’s biggest brain research award goes to European leaders on Aβ tau and TREM2.
Voyager Therapeutics announced positive interim results from a small, ongoing Phase 1b trial in people with advanced PD.
A family of petite, RNA-directed nucleases offers a platform for finessing the transcriptome.
AAIC presentations identified early imaging changes in aging and AD, and reinforced the idea that CSF markers change little over the short term.
At CTAD, a handful of candidate therapies were reported to have flamed out in Phase 2. They were unable to show efficacy. A new antipsychotic is entering the ring.
Recent studies exemplify the burgeoning array of stem cell strategies to treat neurodegeneration, ranging from sending in supportive cells to switching out neurons.
In AIBL, memory declines as people with brain amyloid age. Without amyloid, episodic memory keeps steady, even in ApoE4 carriers.
No filters selected